The aim of the current nationwide, multicentre Austrian study was to investigate systematically the intravenous administration of pantoprazole. The study objectives were to collect and evaluate ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
5monon MSN
Disruptions from Hurricane Helene exacerbated shortages of critical intravenous fluids in the United States, and now the ...
Hosted on MSN11mon
Topical tranexamic acid found inferior to intravenous administration"Topical administration in its current form is inferior to intravenous TxA and should not be used." The trial, called DEPOSITION, intended to enroll 3,800 patients but stopped after enrolling ...
News-Medical.Net on MSN4d
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIVViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback